Venous Thromboembolism Anticoagulation Duration Decision — free guideline decision tool
This tool decides whether VTE anticoagulation stops at 3 months or extends, weighing recurrence risk (by provoking factor) against bleeding risk.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Provoking-factor type | Unprovoked |
|---|---|
| Bleeding risk | Low-moderate |
→Anticoagulation durationExtended anticoagulation (no fixed stop date)
- Decision：Unprovoked VTE carries high recurrence risk with low-moderate bleeding risk, so extended anticoagulation (no fixed stop date) is recommended, and a reduced-dose DOAC may be considered (apixaban or rivaroxaban).
- General rule：All VTE is anticoagulated at least 3 months; those on extended anticoagulation should periodically (e.g. yearly) reassess bleeding risk, benefit, and patient preference
- Bleeding risk：Low-moderate bleeding risk: can tolerate extended anticoagulation
| Provoking-factor type | Major transient (surgery/trauma/prolonged immobilization) |
|---|---|
| Bleeding risk | Low-moderate |
→Anticoagulation durationStop anticoagulation after 3 months
- Decision：Caused by a major transient factor (surgery, trauma, prolonged immobilization), the recurrence risk after stopping is low, and 3 months suffices.
- General rule：All VTE is anticoagulated at least 3 months; those on extended anticoagulation should periodically (e.g. yearly) reassess bleeding risk, benefit, and patient preference
- Bleeding risk：Low-moderate bleeding risk: can tolerate extended anticoagulation
Common questions
What is Venous Thromboembolism Anticoagulation Duration Decision?
This tool decides whether VTE anticoagulation stops at 3 months or extends, weighing recurrence risk (by provoking factor) against bleeding risk.
How is Venous Thromboembolism Anticoagulation Duration Decision calculated? What is the core formula?
Major transient → 3 months. Minor transient → ≥ 3 months, individualized. Cancer → until inactive. Recurrent → extended/indefinite. Unprovoked → extended if low-moderate bleeding (reduced-dose DOAC), stop at 3 months if high bleeding.
When is Venous Thromboembolism Anticoagulation Duration Decision used?
Use to set anticoagulation duration: short course for major transient triggers, indefinite for cancer or recurrence, and bleeding-risk-dependent for unprovoked VTE.
What are the key clinical points for Venous Thromboembolism Anticoagulation Duration Decision?
Unprovoked VTE tips toward extended anticoagulation unless bleeding risk is high, where a 3-month course with possible aspirin is preferred. (original synthesis · not guideline verbatim) All VTE receives at least 3 months of anticoagulation regardless of provoking factor. Extended courses are periodically reassessed for bleeding risk, benefit, and preference.
What are the limits and cautions when using Venous Thromboembolism Anticoagulation Duration Decision?
For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
Does Venous Thromboembolism Anticoagulation Duration Decision upload patient data? Where is it calculated?
Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.
How is Venous Thromboembolism Anticoagulation Duration Decision calculated in practice? Can you show a worked example?
Inputs: Provoking-factor type Unprovoked, Bleeding risk Low-moderate → Result: Anticoagulation duration Extended anticoagulation (no fixed stop date)（Decision: Unprovoked VTE carries high recurrence risk with low-moderate bleeding risk, so extended anticoagulation (no fixed stop date) is recommended, and a reduced-dose DOAC may be considered (apixaban or rivaroxaban)., General rule: All VTE is anticoagulated at least 3 months; those on extended anticoagulation should periodically (e.g. yearly) reassess bleeding risk, benefit, and patient preference, Bleeding risk: Low-moderate bleeding risk: can tolerate extended anticoagulation） Inputs: Provoking-factor type Major transient (surgery/trauma/prolonged immobilization), Bleeding risk Low-moderate → Result: Anticoagulation duration Stop anticoagulation after 3 months（Decision: Caused by a major transient factor (surgery, trauma, prolonged immobilization), the recurrence risk after stopping is low, and 3 months suffices., General rule: All VTE is anticoagulated at least 3 months; those on extended anticoagulation should periodically (e.g. yearly) reassess bleeding risk, benefit, and patient preference, Bleeding risk: Low-moderate bleeding risk: can tolerate extended anticoagulation）
Run Venous Thromboembolism Anticoagulation Duration Decision now
This tool decides whether VTE anticoagulation stops at 3 months or extends, weighing recurrence risk (by provoking factor) against bleeding risk.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.